New antibody drug aims to ease lung blood pressure
NCT ID NCT07318597
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called REGN13335 in 99 adults with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lungs makes the heart work harder. Participants will receive either the drug or a placebo, on top of their usual PAH medications. The goal is to see if REGN13335 safely lowers lung blood pressure and improves heart function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
REGN13335 (an antibody that blocks a protein called PDGF-B)
What this could lead to
If it works, this could lead to a new treatment option for people with pulmonary arterial hypertension, helping to lower blood pressure in the lungs and improve heart function.
What could go wrong
This is a mid-stage trial with only 99 participants, so results may not apply to everyone. The drug is still experimental, and side effects or lack of benefit are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
RECRUITINGSeoul, Songpa-gu, 05505, South Korea
-
Gachon University Gil Medical Center
RECRUITINGNamdong-gu, Incheon, 21565, South Korea
-
Hopital Bicetre
RECRUITINGLe Kremlin-Bicêtre, 94275, France
-
Hospital Universitario Costa del Sol
RECRUITINGMarbella, Malaga, 29603, Spain
-
Imperial College Healthcare NHS Trust, Hammersmith Hospital
RECRUITINGLondon, W12 0HS, United Kingdom
-
P. Stradins Clinical University hospital
RECRUITINGRiga, LV1002, Latvia
-
Royal Hobart Hospital
RECRUITINGHobart, Tasmania, 7000, Australia
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
-
Severance Hospital
RECRUITINGSeoul, 03722, South Korea
-
University of Colorado Denver
RECRUITINGAurora, Colorado, 80045, United States